BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on Gilenya®: new contraindications in patients with cardiac disorders

2017.11.07

Active substance: fingolimod

The company Novartis is circulating information on new contraindications in patients with cardiac disorders.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 426KB, File is accessible